Profound Medical Grows with TULSA Validation | Business and Finance News

Profound Medical’s Q2 earnings reveal strong momentum despite a shipment delay: revenue hit $2.5M, up 12% YoY, with $1.6M from recurring revenue and solid 70%+ gross margins. A $3.1M product delay pushed Q2 figures below what could have been a 153% YoY surge. Clinically, the CAPTAIN trial shows TULSA excels in preserving quality of life—and even penile length—outperforming robotic surgery, boosting insurance coverage potential. With a $70M sales pipeline and expanding Medicare reimbursement, Profound is on track for profitable, scalable growth. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/1ccac7c0ac934a9b